Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: Neurochemistry, motor function and gut barrier.
Biochem Biophys Res Commun
; 556: 16-22, 2021 06 04.
Article
de En
| MEDLINE
| ID: mdl-33836343
ABSTRACT
Evidence suggests constipation precedes motor dysfunction and is the most common gastrointestinal symptom in Parkinson's disease (PD). 5-HT4 receptor (5-HT4R) agonist prucalopride has been approved to treat chronic constipation. Here, we reported intraperitoneal injection of prucalopride for 7 days increased dopamine and decreased dopamine turnover. Prucalopride administration improved motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrathydropyridine (MPTP)-induced PD mouse models. Prucalopride treatment also ameliorated intestinal barrier impairment and increased IL-6 release in PD model mice. However, prucalopride treatment exerted no impact on JAK2/STAT3 pathway, suggesting that prucalopride may stimulate IL-6 via JAK2/STAT3-independent pathway. In conclusion, prucalopride exerted beneficial effects in MPTP-induced Parkinson's disease mice by attenuating the loss of dopamine, improving motor dysfunction and intestinal barrier.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Maladie de Parkinson
/
Benzofuranes
/
1-Méthyl-4-phényl-1,2,3,6-tétrahydropyridine
/
Muqueuse intestinale
/
Aptitudes motrices
Type d'étude:
Prognostic_studies
Limites:
Animals
Langue:
En
Journal:
Biochem Biophys Res Commun
Année:
2021
Type de document:
Article
Pays d'affiliation:
Chine